JP2021530565A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021530565A5 JP2021530565A5 JP2021525358A JP2021525358A JP2021530565A5 JP 2021530565 A5 JP2021530565 A5 JP 2021530565A5 JP 2021525358 A JP2021525358 A JP 2021525358A JP 2021525358 A JP2021525358 A JP 2021525358A JP 2021530565 A5 JP2021530565 A5 JP 2021530565A5
- Authority
- JP
- Japan
- Prior art keywords
- crystalline
- compound iii
- type
- angles
- ray powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000634 powder X-ray diffraction Methods 0.000 claims 6
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims 5
- 238000001757 thermogravimetry curve Methods 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 101001050886 Homo sapiens Lysine-specific histone demethylase 1A Proteins 0.000 claims 1
- 102100024985 Lysine-specific histone demethylase 1A Human genes 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 238000000113 differential scanning calorimetry Methods 0.000 claims 1
- 238000001938 differential scanning calorimetry curve Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000017525 heat dissipation Effects 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810804068 | 2018-07-20 | ||
| CN201810804068.3 | 2018-07-20 | ||
| PCT/CN2019/096842 WO2020015745A1 (zh) | 2018-07-20 | 2019-07-19 | 一种lsd1抑制剂的盐及其晶型 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021530565A JP2021530565A (ja) | 2021-11-11 |
| JP2021530565A5 true JP2021530565A5 (https=) | 2021-12-23 |
| JP7358466B2 JP7358466B2 (ja) | 2023-10-10 |
Family
ID=69163657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021525358A Active JP7358466B2 (ja) | 2018-07-20 | 2019-07-19 | Ｌｓｄ１阻害剤の塩及びその結晶型 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12024494B2 (https=) |
| EP (1) | EP3825309B1 (https=) |
| JP (1) | JP7358466B2 (https=) |
| KR (1) | KR102778948B1 (https=) |
| CN (1) | CN112424175B (https=) |
| AU (1) | AU2019303777B2 (https=) |
| CA (1) | CA3106484C (https=) |
| WO (1) | WO2020015745A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021228146A1 (zh) * | 2020-05-12 | 2021-11-18 | 石药集团中奇制药技术（石家庄）有限公司 | 一种lsd1抑制剂的用途 |
| US20250073232A1 (en) | 2021-04-08 | 2025-03-06 | Oryzon Genomics, S.A. | Combinations of lsd1 inhibitors for treating myeloid cancers |
| EP4522136A1 (en) | 2022-05-09 | 2025-03-19 | Oryzon Genomics, S.A. | Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors |
| US20250295660A1 (en) | 2022-05-09 | 2025-09-25 | Oryzon Genomics, S.A. | Methods of treating nf1-mutant tumors using lsd1 inhibitors |
| CN120529900A (zh) | 2022-11-24 | 2025-08-22 | 奥莱松基因组股份有限公司 | 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合 |
| CN116069221A (zh) * | 2022-12-27 | 2023-05-05 | 北京字跳网络技术有限公司 | 媒体内容的展示方法、装置、电子设备和存储介质 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2705675B1 (fr) * | 1993-05-27 | 1996-05-03 | Smithkline Beecham Labo Pharma | Nouveaux composés, leur procédé de préparation et leur utilisation en tant que médicaments. |
| US8993808B2 (en) * | 2009-01-21 | 2015-03-31 | Oryzon Genomics, S.A. | Phenylcyclopropylamine derivatives and their medical use |
| CA2796726C (en) | 2010-04-19 | 2021-02-16 | Oryzon Genomics S.A. | Lysine specific demethylase-1 inhibitors and their use |
| BR112013002164B1 (pt) * | 2010-07-29 | 2021-11-09 | Oryzon Genomics S.A. | Inibidores de desmetilase à base de arilciclopropilamina de lsd1, seus usos, e composição farmacêutica |
| PH12013501871A1 (en) | 2011-03-25 | 2019-06-03 | Glaxosmithkline Ip No 2 Ltd | Cyclopropylamines as lsd1 inhibitors |
| MY189367A (en) * | 2015-08-12 | 2022-02-08 | Incyte Corp | Salts of an lsd1 inhibitor |
| TWI833686B (zh) * | 2016-04-22 | 2024-03-01 | 美商英塞特公司 | Lsd1 抑制劑之調配物 |
| PT3455204T (pt) | 2016-05-09 | 2026-01-27 | Jubilant Epicore LLC | Compostos de ciclopropil-amida como inibidores duplos de lsd1/hdac |
| US11433053B2 (en) | 2017-01-24 | 2022-09-06 | Medshine Discovery Inc. | LSD1 inhibitor and preparation method and application thereof |
-
2019
- 2019-07-19 CA CA3106484A patent/CA3106484C/en active Active
- 2019-07-19 JP JP2021525358A patent/JP7358466B2/ja active Active
- 2019-07-19 WO PCT/CN2019/096842 patent/WO2020015745A1/zh not_active Ceased
- 2019-07-19 AU AU2019303777A patent/AU2019303777B2/en active Active
- 2019-07-19 CN CN201980047189.0A patent/CN112424175B/zh active Active
- 2019-07-19 KR KR1020217005112A patent/KR102778948B1/ko active Active
- 2019-07-19 US US17/261,322 patent/US12024494B2/en active Active
- 2019-07-19 EP EP19837636.0A patent/EP3825309B1/en active Active